Luigi Moro

This inventor holds 32 USPTO granted patents and 19 published patent applications, plus 7 CIPO patents and 16 EPO patents. Top assignees: Cosmo Technologies Limited, Cassiopea S.p.a., Farmitalia Carlo Erba. Active years: 1984-2025.

USPTO Granted Patents = 32 (Patent Applications = 19)

% Patents Active = 90.6

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 16 (Patent Applications = 15)

Average Co-Inventor Count = 2.7

ph-index = 9

Forward Citations = 163(Granted Patents)

Location History:

Milan, IT (2015)
Lainate (Milano), IT (2016)
Cairate, IT (1984 - 2024)
Lainate, IT (2014 - 2024)

Company Filing History:

17 out of 50

Cosmo Technologies Limited

Farmitalia Carlo Erba

Years Active: 1984-2025

Loading Chart...

Areas of Expertise:

Enzymatic Processes

Cortexolone Monoesters

Endoscopic Mucosal Resection

Microemulsions

Oral Pharmaceutical Compositions

Heparin Derivatives

Antiandrogenic Agents

Diagnostic Endoscopy

Solid Pharmaceutical Compositions

Liquid Emulsions

Sustained-Release Formulations

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12337002 - Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives (2025-06-24),

2. 12036316 - Oral rifamycin SV compositions (2024-07-16),

3. 11938141 - Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives (2024-03-26),

4. 11564883 - Oral rifamycin SV compositions (2023-01-31),

5. 11207332 - Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives (2021-12-28),

6. 11123460 - Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection (2021-09-21),

7. 10925978 - Liquid composition in the form of emulsion or microemulsion for rectal administration containing at least one dye, and its use in a diagnostic endoscopic procedure of sigmoid colon and/or rectum (2021-02-23),

8. 10849979 - Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection (2020-12-01),

9. 10716796 - Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives (2020-07-21),

10. 10413611 - Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection (2019-09-17),

11. 10265420 - Solid composition for the oral administration of dyes and diagnostic use thereof (2019-04-23),

12. 10166245 - Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives (2019-01-01),

13. 10159682 - Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives (2018-12-25),

14. 9987366 - Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection (2018-06-05),

15. 9962445 - Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection (2018-05-08),

Title: Luigi Moro: Innovator in Pharmaceutical Patents

Introduction

Luigi Moro, based in Cairate, Italy, stands out as a prolific inventor with an impressive portfolio of 31 patents. His work primarily focuses on advancements in pharmaceutical formulations designed to address various medical conditions.

Latest Patents

Among his latest innovations, Moro has developed oral rifamycin SV compositions that present a higher strength formulation aimed at improving therapeutic profiles within the small intestine. This invention is particularly beneficial in preventing and treating conditions such as small intestine bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), cholera, hepatic encephalopathy, hepatic cirrhosis, pouchitis, and non-alcoholic fatty liver disease. In addition, he has created a novel enzymatic process for obtaining 17α-monoesters of cortexolone and its derivatives, highlighting his dedication to advancing pharmaceutical science through innovative methods.

Career Highlights

Throughout his career, Luigi Moro has made significant contributions to the pharmaceutical industry while working with reputable companies such as Cosmo Technologies Limited and Cassiopea S.p.a. His efforts in these roles have not only advanced his own expertise but have greatly contributed to the field of medicinal chemistry.

Collaborations

Moro has collaborated with esteemed colleagues including Mauro Ajani and Alessandro Repici. These partnerships have facilitated the exchange of ideas and amplified the impact of his inventions within the pharmaceutical landscape.

Conclusion

Luigi Moro continues to push the boundaries of innovation in pharmaceuticals with his extensive patent portfolio. His work exemplifies the critical nature of research and development in creating effective treatment solutions for various health issues. As he progresses in his career, his contributions are sure to influence the future of medical therapies.